par Zlotta, Alexandre 
;Drowart, Annie ;Van Vooren, Jean-Paul ;Shekarsarai, H;Decock, Michel ;Pirson, Michel ;Palfliet, Kamiel;Jurion, F;Simon, Jacques ;Schulman, Claude ;Huygen, Kris
Référence The Journal of urology, 159, 6, page (1885-1891)
Publication Publié, 1998-06
;Drowart, Annie ;Van Vooren, Jean-Paul ;Shekarsarai, H;Decock, Michel ;Pirson, Michel ;Palfliet, Kamiel;Jurion, F;Simon, Jacques ;Schulman, Claude ;Huygen, KrisRéférence The Journal of urology, 159, 6, page (1885-1891)
Publication Publié, 1998-06
Article révisé par les pairs
| Résumé : | The precise mechanism of action of bacillus Calmette-Guerin (BCG) in bladder cancer treatment remains poorly understood. Whether bladder tumor cells are destroyed by nonspecific mechanisms or targeted by specifically activated lymphocytes recognizing cognate antigens is unclear. To investigate a possible cross-reactivity between BCG and bladder cell tumors, we tested before BCG treatment the lymphoproliferation of peripheral blood lymphocytes against several mycobacterial antigens, including the secreted fibronectin binding antigen 85 complex from BCG (AG 85) in patients with superficial bladder tumors compared to control matched patients. |
